The results of the SLLIP analysis have been scheduled for presentation in a Poster Session at the AACR Annual Meeting 2019 in Atlanta, Georgia, and were published in the 2019 Proceedings of the AACR.
SLLIP was a multi¬center observational study in patients with treatment¬naïve metastatic LUAC. In this prospective, multicenter study, blood samples from treatment-naïve stage IIIB-IV NSCLC patients were tested using a well-validated comprehensive next-generation sequencing (NGS) cfDNA panel (Guardant360TM) and compared with SOC tissue testing.
As a conclusion, this is the first prospective, multi-center study reporting outcomes and demonstrating that a comprehensive and highly sensitive cfDNA NGS assay is non-inferior to SOC tissue testing for the detection of guideline-recommended actionable genomic alterations in NSCLC.
The PPV of the cfDNA assay utilized was high, supporting the use of cfDNA in treatment selection, which was confirmed with PFS and overall response rates similar to those previously reported.
By modeling a blood-first approach to genotyping, comprehensive cfDNA testing identified 80.7% of the patients with informative biomarkers, while SOC tissue testing identified 57.1%. These results are confirmed in a parallel prospective, multicenter North American study.
To sum up, the analysis of the SLLIP project has demonstrated the clinical utility of comprehensive cfDNA genotyping to identify targetable biomarkers in newly diagnosed advanced NSCLC patients.
